mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor

Cancer Research

Volumn 67, Issue 24, 2007, Pages 11712-11720

  Masri, Janine ^a   Bernath, Andrew ^a   Martin, Jheralyn ^a   Jo, Oak D ^a   Vartanian, Raffi ^a   Funk, Alexander ^a   Gera, Joseph ^a,b  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; BETA3 INTEGRIN; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MLST8 PROTEIN; MSIN1 PROTEIN; MTORC2 PROTEIN; PROTEIN KINASE C ALPHA; RAPAMYCIN; REGULATOR PROTEIN; RICTOR PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL CYCLE S PHASE; CELL MOTILITY; CELL PROLIFERATION; CELLULAR DISTRIBUTION; COMPLEX FORMATION; CONJUGATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOSKELETON; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; GENE OVEREXPRESSION; GLIOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN FUNCTION; TUMOR GROWTH;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BRAIN NEOPLASMS; CARRIER PROTEINS; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CELL MOVEMENT; COLONY-FORMING UNITS ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; LENTIVIRUS; NEOPLASM INVASIVENESS; PLASMIDS; PROMOTER REGIONS (GENETICS); PROTEIN KINASE C-ALPHA; PROTEIN KINASES; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 37549048521     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2223     Document Type: Article

References (50)

1. Kim L, Glantz M. Chemotherapeutic options for primary brain tumors. Curr Treat Options Oncol 2006;7:467-78.
2. Penas-Prado M, Gilbert MR. Molecularly targeted therapies for malignant gliomas: advances and challenges. Expert Rev Anticancer Ther 2007;7:641-61.
3. Davis F, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary brain tumors stratified by patient age and tumor histological type: an analysis based on surveillance, epidemiology and end results (SEER) data. J Neurosurg 1998;88:1-10.
4. Holland EC. Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet 2001;2:120-9.
5. Hulleman E, Helin, K. Molecular mechanisms in gliomagenesis. Adv Cancer Res 2005;94:1-27.
6. Konopka G, Bonni A. Signaling pathways regulating gliomagenesis. Curr Mol Med 2003;3:73-84.
7. Dai C, Holland EC. Glioma models. Biochim Biophys Acta 2001;1551:M19-27.
8. Rickman DS, Bobek MP, Misek DE, et al. Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res 2001;61:6885-91.
9. Sallinen S, Sallinen PK, Haapasalo HK, et al. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res 2000;60:6617-22.
10. Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med 2005;11:353-61.
11. Abraham RT. TOR signaling: an odyssey from cellular stress to the cell growth machinery. Curr Biol 2005;15:R139-41.
12. Easton JB, Houghton PJ. Therapeutic potential of target of rapamycin inhibitors. Expert Opin Ther Targets 2004;8:551-64.
13. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004;23:3151-71.
14. Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004;14:1296-302.
15. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006;22:159-68.
16. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926-45.
17. Richter JD, Sonenberg N. Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 2005;433:477-80.
18. Kim DH, Sabatini DM. Raptor and mTOR: subunits of a nutrient-sensitive complex. Curr Top Microbiol Immunol 2004;279:259-70.
19. Houghton PJ, Huang S. mTOR as a target for cancer therapy. Curr Top Microbiol Immunol 2004;279:339-59.
20. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098-101.
21. Hresko RC, Mueckler M. mTOR-RICTOR is the ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem 2005;280:40406-16.
22. Haas-Kogan D, Shalev N, Wong M, Mills G, Yount G, Stokoe D. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol 1998;8:1195-9.
23. Ermoian RP, Furniss CS, Lamborn KR, et al. Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Clin Cancer Res 2002;8:1100-6.
24. Moffat J, Grueneberg DA, Yang X, et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006;124:1283-98.
25. Stewart SA, Dykxhoorn DM, Palliser D, et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 2003;9:493-501.
26. Marderosian M, Sharma A, Funk AP, et al. Tristetraprolin regulates cyclin D1 and c-myc mRNA stability in response to rapamycin in an Akt-dependent manner via p38 MAPK signaling. Oncogene 2006;25:6277-90.
27. Sharma A, Masri J, Jo OD, et al. Protein kinase C regulates internal initiation of translation of the GATA-4 mRNA following vasopressin-induced hypertrophy of cardiac myocytes. J Biol Chem 2007;282:9505-16.
28. Applied Biosystems. User Bulletin #2: relative quantification of gene expression. Foster City (CA): Applied Biosystems; 1997.
29. Shi Y, Sharma A, Wu H, Lichtenstein A, Gera J. Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway. J Biol Chem 2005;280:10964-73.
30. Gera JF, Mellinghoff IK, Shi Y, et al. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 2004;279:2737-46.
31. Xie D, Miller CW, O'Kelly J, et al. Breast Cancer. Cyr61 is overexpressed, estrogen-inducible, and associates with more advanced disease. J Biol Chem 2001;276:14187-94.
32. Schmidt A, Bickle M, Beck T, Hall MN. The yeast phosphatidylinositol kinase homologue TOR2 activates RHO1 and RHO2 via the exchange factor ROM2. Cell 1997;88:531-42.
33. Ivaska J, Kermorgant S, Whelan R, et al. Intergrin-protein kinase C relationships. Biochem Soc Trans 2003;31:90-3.
34. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006;6:729-34.
35. Kapoor G, O'Rourke D. Receptor tyrosine kinase signaling in gliomagenesis: pathology and therapeutic approaches. Cancer Biol Ther 2003;2:330-42.
36. Dummler B, Hemmings B. Physiological roles of PKB/Akt isoforms in development and disease. Biochem Soc Trans 2007;35:231-5.
37. Larsson C. Protein kinase C and the regulation of the actin cytoskeleton. Cell Signal 2006;18:276-84.
38. Guertin DA, Stevens DM, Thoreen CC, et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCα, but not S6K1. Dev Cell 2006;11:859-71.
39. Yang Q, Inoki K, Ikenoue T, Guan KL. Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev 2006;20:2820-32.
40. Pearce L, Huang X, Boudeau J, et al. Identification of protor as a novel rictor-binding component of mTOR-complex-2. Biochem J 2007;405:513-22.
41. Furnari FB, Lin H, Huang H, Cavenee WK. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc Natl Acad Sci U S A 1997;94:12479-84.
42. Krex D, Mohr B, Hauses M, et al. Identification of uncommon chromosomal aberrations in the neuroglioma cell line H4 by spectral karyotyping. J Neurooncol 2001;52:119-28.
43. Guo W, Giancotti FG. Integrin signaling during tumour progression. Nat Rev Mol Cell Biol 2004;5:816-26.
44. Bello L, Francolini M, Marthyn P, et al. α(v)β3 and α(v)β5 integrin expression in glioma periphery. Neurosurgery 2001;49:380-9.
45. Chatterjee S, Matsumura A, Schradermaier J, Gillespie G. Human malignant glioma therapy using anti-α(v)β3 integrin agents. J Neurooncol 2000;46:135-44.
46. 3 overexpression in glioblastoma multiforme. Cancer Res 2004;64:2751-8.
47. 3 expression on glioma growth and angiogenesis. J Biol Chem 2006;281:37256-64.
48. 1 integrin-dependent cell motility through association and control of integrin traffic. EMBO J 1999;18:3909-23.
49. Qiao M, Iglehart JD, Pardee AB. Metastatic potential of 21T human breast cancer cells depends on Akt/ protein kinase B activation. Cancer Res 2007;67:5293-9.
50. Gao T, Furnari F, Newton AC. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 2005;18:13-25.